Maeoka, R.; Nakazawa, T.; Matsuda, R.; Morimoto, T.; Shida, Y.; Yamada, S.; Nishimura, F.; Nakamura, M.; Nakagawa, I.; Park, Y.-S.;
et al. Therapeutic Anti-KIR Antibody of 1–7F9 Attenuates the Antitumor Effects of Expanded and Activated Human Primary Natural Killer Cells on In Vitro Glioblastoma-like Cells and Orthotopic Tumors Derived Therefrom. Int. J. Mol. Sci. 2023, 24, 14183.
https://doi.org/10.3390/ijms241814183
AMA Style
Maeoka R, Nakazawa T, Matsuda R, Morimoto T, Shida Y, Yamada S, Nishimura F, Nakamura M, Nakagawa I, Park Y-S,
et al. Therapeutic Anti-KIR Antibody of 1–7F9 Attenuates the Antitumor Effects of Expanded and Activated Human Primary Natural Killer Cells on In Vitro Glioblastoma-like Cells and Orthotopic Tumors Derived Therefrom. International Journal of Molecular Sciences. 2023; 24(18):14183.
https://doi.org/10.3390/ijms241814183
Chicago/Turabian Style
Maeoka, Ryosuke, Tsutomu Nakazawa, Ryosuke Matsuda, Takayuki Morimoto, Yoichi Shida, Shuichi Yamada, Fumihiko Nishimura, Mitsutoshi Nakamura, Ichiro Nakagawa, Young-Soo Park,
and et al. 2023. "Therapeutic Anti-KIR Antibody of 1–7F9 Attenuates the Antitumor Effects of Expanded and Activated Human Primary Natural Killer Cells on In Vitro Glioblastoma-like Cells and Orthotopic Tumors Derived Therefrom" International Journal of Molecular Sciences 24, no. 18: 14183.
https://doi.org/10.3390/ijms241814183
APA Style
Maeoka, R., Nakazawa, T., Matsuda, R., Morimoto, T., Shida, Y., Yamada, S., Nishimura, F., Nakamura, M., Nakagawa, I., Park, Y.-S., Tsujimura, T., & Nakase, H.
(2023). Therapeutic Anti-KIR Antibody of 1–7F9 Attenuates the Antitumor Effects of Expanded and Activated Human Primary Natural Killer Cells on In Vitro Glioblastoma-like Cells and Orthotopic Tumors Derived Therefrom. International Journal of Molecular Sciences, 24(18), 14183.
https://doi.org/10.3390/ijms241814183
